...Adina Wise; Hernan Nicolas Lemus; Madeline Fields; Matthew Swan; Susan Bressman Carbidopa-levodopa has been used for more than 50 years in the treatment of Parkinson disease (PD) and other movement disorders. Pyridoxal 5′-phosphate (PLP), an active form of vitamin B6 (pyridoxine), is involved...

... of neurological involvement. Its median age of onset has been reported to be around 40 years. We report herein a case of very-late-onset NMOSD (76 years of age) and try to promote its awareness as a type of neurological deterioration in elder patients. A 76-year-old woman suffering from Parkinson disease...

...Hiromasa Sato; Toshiyuki Yamamoto; Masako Sato; Yoshihiko Furusawa; Miho Murata Objective: The causes of “delayed-on” and “no-on” phenomena in Parkinson disease (PD) are thought to have some impact on the progress of L-DOPA from the time of ingestion until it reaches the brain and is converted...

...Antti Huotarinen; Martin Reich; Jens Volkmann; Eero Pekkonen Background: STB DBS (deep brain stimulation of the subthalamic nucleus) is commonly used to treat advanced Parkinson disease (PD) while posterior hypothalamic DBS for cluster headache (CH) remains experimental. Methods: We present a case...

...Franz Marxreiter; Jürgen Winkler; Martin Uhl; Dominik Madžar Amantadine is frequently used in addition to dopaminergic substances like dopamine agonists or L-Dopa in advanced Parkinson disease (PD). However, adverse effects like hallucinations limit its use. PD patients developing severe psychotic...